Understanding how a specific protein affects neuron health in Alzheimer's disease
Neuronal ApoE Drives Selective Neurodegeneration in Alzheimer's Disease
This study is looking at how a specific protein called apoE, especially the apoE4 version, affects certain brain cells in Alzheimer's disease to help us understand why some cells get damaged more than others, which could lead to better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11115632 on NIH RePORTER |
What this research studies
This research investigates the role of apolipoprotein E (apoE) in the selective degeneration of neurons in Alzheimer's disease. By utilizing advanced single-cell analysis techniques, the study aims to uncover why certain neurons are more vulnerable to damage than others, particularly focusing on the effects of the apoE4 variant. The research will explore how neuronal apoE4 impacts synaptic health and contributes to neurodegeneration, potentially leading to new insights into Alzheimer's pathology. Patients may benefit from a better understanding of the disease mechanisms, which could inform future therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for Alzheimer's disease, particularly those with the apoE4 genetic variant.
Not a fit: Patients without any genetic predisposition to Alzheimer's disease or those with advanced stages of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect neurons and slow the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in understanding the role of apoE in neurodegeneration, suggesting that this approach could yield valuable insights.
Where this research is happening
San Francisco, United States
- J. David Gladstone Institutes — San Francisco, United States (Active)
Researchers
- Principal investigator: Huang, Yadong — J. David Gladstone Institutes
- Study coordinator: Huang, Yadong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.